Join us for an Xtalks webinar:
Traditional assessments alone may not fully capture disease progression or treatment response in neurodegenerative disease clinical trials. This webinar explores how biological, imaging, digital, and wearable biomarkers are enabling earlier detection, more precise patient characterization, improved monitoring of disease progression, and better evaluation of treatment effects. Attendees will learn how these innovative approaches can strengthen clinical trial design, support personalized medicine, and accelerate the development of next-generation therapies for neurodegenerative diseases. Real-world applications, implementation considerations, and emerging trends shaping the future of CNS research will also be discussed.
What You Will Learn
- How biological, digital, imaging and wearable biomarkers can support earlier detection and more precise assessment of neurodegenerative diseases
- How biomarker data can strengthen patient selection, clinical trial design and development of more personalized therapies
- How digital health technologies and wearable devices can monitor disease progression and treatment response
- Key considerations and evolving trends influencing biomarker-driven CNS drug development and precision medicine
Who Should Attend
This webinar is designed for clinical development leaders, clinical research scientists, neuroscience and CNS researchers, biomarker experts, translational medicine scientists, and digital health leaders.
Speakers
Bob Dagher, MD | Chief Medical Officer | Clinilabs
Nicklas Linz | CEO and Co-Founder | Ki:elements
Chiara Capra | Co-Founder and CEO, LIFE Neurotech & CPO, Sense4Care
Event Information
When: Tuesday, November 10, 2026
Time: 12pm EDT (NA) / 5pm BST (UK) / 6pm CEST (EU-Central)
Duration: 60 minutes | Live & QA
